This Article Full Text Full Text (PDF) All Versions of this Article: 145/6/2876    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Corbani, M. Articles by Meunier, J.-C. Search for Related Content PubMed PubMed Citation Articles by Corbani, M. Articles by Meunier, J.-C.

Ligand-Regulated Internalization of the Opioid Receptor-Like 1: A Confocal Study

Institut de Pharmacologie et de Biologie Structurale (M.C., J.-C.M.), Centre National de la Recherche Scientifique, 31017 Toulouse, and the Institut Européen de Biologie Cellulaire (C.G.), 31520 Ramonville-Sainte-Agne, France

Address all correspondence and requests for reprints to: Maithé Corbani, Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique-Unité Mixte de Recherche 5089, 205 route de Narbonne 31017 Toulouse cedex 4, France. E-mail: maithe.corbani{at}ipbs.fr.

To better understand opioid receptor-like 1 (ORL1) internalization, we fused the C terminus of ORL1, the nociceptin (noc) receptor, to the N terminus of a green fluorescent protein and used the fusion protein to characterize receptor endocytosis in live human embryonic kidney cells. The fusion altered neither the affinity of the receptor for noc or other ORL1 receptor ligands nor the ability of the receptor to mediate agonist-induced binding of GTP³⁵S, i.e. coupling with heterotrimeric G protein. Confocal microscopy showed that the fluorescent receptor was mostly associated (>75%) with the periplasmic membrane. In the presence of 0.1 µM noc, approximately 80% of receptors were internalized, and half-maximum internalization was reached in approximately 12 min at 22 C and approximately 6 min at 37 C. After washing, a normal receptor level was recovered within 70 min at 22 C. The lack of internalization in the presence of 0.45 M sucrose suggests that noc-induced receptor endocytosis mainly occurred via clathrin-coated pits. Coincubation of the recombinant cells with noc and tetramethylrhodamine-transferrin showed that ORL1 was mainly internalized through the endosome compartment. Lofentanil and Ro64-6198 ([(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one]) promoted endocytosis of the fluorescent receptor as efficiently as noc. Among the two ORL1 receptor antagonists, J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one), but not III-BTD, blocked the noc-induced internalization of the fluorescent receptor. Two partial agonists were dramatically less efficient than noc to promote ORL1 internalization. They recruited very little (the pseudopeptide [Phe¹(CH₂-NH)Gly²]-noc-(1–13)NH₂) or no (the hexapeptide Ac-Arg-Tyr-Tyr-Lys-Trp-Arg-NH₂) G protein receptor kinase type 2 coupled to red fluorescent protein 1 at the membrane, suggesting that subsequent receptor phosphorylation necessary for internalization via coated pits is altered. Thus, partial agonists that induce a prolonged cell response without causing substantial receptor internalization may be good tools for further clinical treatments.

This article has been cited by other articles:

				D. R. Kapusta, C. Thorkildsen, V. A. Kenigs, E. Meier, M. M. Vinge, C. Quist, and J. S. Petersen Pharmacodynamic Characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a Novel, Functionally Selective Nociceptin/Orphanin FQ Peptide Receptor Partial Agonist with Sodium-Potassium-Sparing Aquaretic Activity J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 652 - 660. [Abstract] [Full Text] [PDF]

				D. R. Kapusta, M. A. Burmeister, G. Calo', R. Guerrini, H. B. Gottlieb, and V. A. Kenigs Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 643 - 651. [Abstract] [Full Text] [PDF]